Monoclonal Antibodies for Multiple Sclerosis: An Update

1.

Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391:1622–36. https://doi.org/10.1016/S0140-6736(18)30481-1.CrossRefPubMed

2.

Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72(Suppl 1):1–5. https://doi.org/10.1159/000367614.CrossRefPubMed

3.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86. https://doi.org/10.1212/WNL.0000000000000560.CrossRefPubMedPubMedCentral

4.

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:789–800. https://doi.org/10.1212/WNL.0000000000005345.CrossRefPubMed

5.

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777–88. https://doi.org/10.1212/WNL.0000000000005347.CrossRefPubMed

6.

Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs. 2018;10:183–203. https://doi.org/10.1080/19420862.2018.1415671.CrossRefPubMedPubMedCentral

7.

Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016;354:i3518. https://doi.org/10.1136/bmj.i3518.CrossRefPubMed

8.

Soelberg Sorensen P. Safety concerns and risk management of multiple sclerosis therapies. Acta Neurol Scand. 2017;136:168–86. https://doi.org/10.1111/ane.12712.CrossRef

9.

Winkelmann A, Loebermann M, Reisinger EC, Hartung H-P, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol. 2016;12:217–33. https://doi.org/10.1038/nrneurol.2016.21.CrossRefPubMed

10.

Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GPA, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15–23. https://doi.org/10.1056/NEJMoa020696.CrossRefPubMed

11.

Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910. https://doi.org/10.1056/NEJMoa044397.CrossRefPubMed

12.

Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–60. https://doi.org/10.1016/S1474-4422(09)70021-3.CrossRefPubMed

13.

Oshima Y, Tanimoto T, Yuji K, Tojo A. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler. 2018. https://doi.org/10.1177/1352458518786075.CrossRefPubMed

14.

Biogen. Biogen internal data. Safety update on natalizumab; September 2018. www.tysabri.de. Accessed 10 Dec 2018.

15.

Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, et al. Efficacy and safety of natalizumab in multiple sclerosis: Interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85:1190–7. https://doi.org/10.1136/jnnp-2013-306936.CrossRefPubMedPubMedCentral

16.

Lorefice L, Fenu G, Gerevini S, Frau J, Coghe G, Barracciu MA, et al. PML in a person with multiple sclerosis: is teriflunomide the felon? Neurology. 2018;90:83–5. https://doi.org/10.1212/WNL.0000000000004804.CrossRefPubMed

17.

Bauer J, Gold R, Adams O, Lassmann H. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS). Acta Neuropathol. 2015;130:751–64. https://doi.org/10.1007/s00401-015-1471-7.CrossRefPubMed

18.

Major EO, Yousry TA, Clifford DB. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol. 2018;17:467–80. https://doi.org/10.1016/S1474-4422(18)30040-1.CrossRefPubMed

19.

Ho P-R, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16:925–33. https://doi.org/10.1016/S1474-4422(17)30282-X.CrossRefPubMed

20.

Warnke C, Ramanujam R, Plavina T, Bergström T, Goelz S, Subramanyam M, et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry. 2013;84:1199–205. https://doi.org/10.1136/jnnp-2012-304332.CrossRefPubMedPubMedCentral

21.

Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:802–12. https://doi.org/10.1002/ana.24286.CrossRefPubMed

22.

Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology. 2017;89:1584–93. https://doi.org/10.1212/WNL.0000000000004485.CrossRefPubMedPubMedCentral

23.

Bianco A, Rossini PM, Mirabella M. Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved. JAMA Neurol. 2014;71:924–5. https://doi.org/10.1001/jamaneurol.2014.1135.CrossRefPubMed

24.

Derfuss T, Kovarik JM, Kappos L, Savelieva M, Chhabra R, Thakur A, et al. α4-integrin receptor desaturation and disease activity return after natalizumab cessation. Neurol Neuroimmunol Neuroinflamm. 2017;4:e388. https://doi.org/10.1212/NXI.0000000000000388.CrossRefPubMedPubMedCentral

25.

Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80:1430–8. https://doi.org/10.1212/WNL.0b013e31828c2fa1.CrossRefPubMedPubMedCentral

26.

Wijburg MT, Warnke C, Barkhof F, Uitdehaag BMJ, Killestein J, Wattjes MP. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort. J Neurol Neurosurg Psychiatry. 2018. https://doi.org/10.1136/jnnp-2018-318261.CrossRefPubMed

27.

Peters J, Williamson E. Natalizumab therapy is associated with changes in serum JC virus antibody indices over time. J Neurol. 2017;264:2409–12. https://doi.org/10.1007/s00415-017-8643-4.CrossRefPubMed

28.

Koolaji S, Allahabadi NS, Ahmadi A, Eskandarieh S, Moghadasi AN, Azimi AR, et al. Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence. J Neurovirol. 2018;24(5):570–6. https://doi.org/10.1007/s13365-018-0646-0.CrossRefPubMed

29.

van Kempen Z, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. Mult Scler. 2017;23:995–9. https://doi.org/10.1177/1352458516684023.CrossRefPubMed

30.

Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, et al. Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. Ann Neurol. 2017;82:186–95. https://doi.org/10.1002/ana.24987.CrossRefPubMed

31.

Antoniol C, Stankoff B. Immunological markers for PML prediction in MS patients treated with natalizumab. Front Immunol. 2014;5:668. https://doi.org/10.3389/fimmu.2014.00668.CrossRefPubMed

32.

Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013;81:865–71. https://doi.org/10.1212/WNL.0b013e3182a351fb.CrossRefPubMed

33.

Lieberman LA, Zeng W, Singh C, Wang W, Otipoby KL, Loh C, et al. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology. 2016;86:375–81. https://doi.org/10.1212/WNL.0000000000002314.CrossRefPubMedPubMedCentral

34.

Scarpazza C, Prosperini L, De Rossi N, Moiola L, Sormani MP, Gerevini S, Capra R. To do or not to do? Plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. Ann Neurol. 2017;82:697–705. https://doi.org/10.1002/ana.25070.CrossRefPubMed

35.

Landi D, de Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, et al. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017;88:1144–52. https://doi.org/10.1212/WNL.0000000000003740.CrossRefPubMed

36.

Yamout BI, Sahraian MA, Ayoubi NE, Tamim H, Nicolas J, Khoury SJ, et al. Efficacy and safety of natalizumab extended interval dosing. Mult Scler Relat Disord. 2018;24:113–6. https://doi.org/10.1016/j.msard.2018.06.015.CrossRefPubMed

37.

Kapoor R, Ho P-R, Campbell N, Chang I, Deykin A, Forrestal F, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018;17:405–15. https://doi.org/10.1016/S1474-4422(18)30069-3.CrossRefPubMed

38.

Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013;191:5867–74. https://doi.org/10.4049/jimmunol.1301926.CrossRefPubMed

39.

Hartung H-P, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler. 2015;21:22–34. https://doi.org/10.1177/1352458514549398.CrossRefPubMedPubMedCentral

40.

Coles AJ, Compston DAS, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786–801. https://doi.org/10.1056/NEJMoa0802670.CrossRefPubMed

41.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–28. https://doi.org/10.1016/S0140-6736(12)61769-3.CrossRefPubMed

42.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–39. https://doi.org/10.1016/S0140-6736(12)61768-1.CrossRefPubMed

43.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011;10:338–48. https://doi.org/10.1016/S1474-4422(11)70020-5.CrossRefPubMed

44.

Hartung H-P, Aktas O. Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. Lancet Neurol. 2011;10:293–5. https://doi.org/10.1016/S1474-4422(11)70043-6.CrossRefPubMed

45.

Havrdova E, Arnold DL, Cohen JA, Hartung H-P, Fox EJ, Giovannoni G, et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology. 2017;89:1107–16. https://doi.org/10.1212/WNL.0000000000004313.CrossRefPubMedPubMedCentral

46.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung H-P, Havrdova E, et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017;89:1117–26. https://doi.org/10.1212/WNL.0000000000004354.CrossRefPubMedPubMedCentral

47.

Giovannoni G, Cohen JA, Coles AJ, Hartung H-P, Havrdova E, Selmaj KW, et al. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology. 2016;87:1985–92. https://doi.org/10.1212/WNL.0000000000003319.CrossRefPubMedPubMedCentral

48.

Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol. 2017;16:271–81. https://doi.org/10.1016/S1474-4422(17)30007-8.CrossRefPubMed

49.

Lizak N, Lugaresi A, Alroughani R, Lechner-Scott J, Slee M, Havrdova E, et al. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. J Neurol Neurosurg Psychiatry. 2017;88:196–203. https://doi.org/10.1136/jnnp-2016-313976.CrossRefPubMed

50.

Zimmermann M, Brouwer E, Tice JA, Seidner M, Loos AM, Liu S, et al. Disease-modifying therapies for relapsing-remitting and primary progressive multiple sclerosis: a cost-utility analysis. CNS Drugs. 2018. https://doi.org/10.1007/s40263-018-0566-9.CrossRefPubMed

51.

Haghikia A, Dendrou CA, Schneider R, Grüter T, Postert T, Matzke M, et al. Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. Lancet Neurol. 2017;16:104–6. https://doi.org/10.1016/S1474-4422(16)30382-9.CrossRefPubMed

52.

Wehrum T, Beume L-A, Stich O, Mader I, Mäurer M, Czaplinski A, et al. Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis. Neurology. 2018;90:e601–5. https://doi.org/10.1212/WNL.0000000000004950.CrossRefPubMed

53.

Barton J, Hardy TA, Riminton S, Reddel SW, Barnett Y, Coles A, Barnett MH. Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. Neurology. 2017;88:1004–6. https://doi.org/10.1212/WNL.0000000000003694.CrossRefPubMed

54.

Pfeuffer S, Beuker C, Ruck T, Lenze F, Wiendl H, Melzer N, Meuth SG. Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS. Neurology. 2016;87:2380–1. https://doi.org/10.1212/WNL.0000000000003379.CrossRefPubMed

55.

Sauer E-M, Schliep S, Manger B, Lee D-H, Linker RA. Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2018;5:e488. https://doi.org/10.1212/NXI.0000000000000488.CrossRefPubMedPubMedCentral

56.

Graf J, Ringelstein M, Lepka K, Schaller J, Quack H, Hartung H-P, et al. Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment. Mult Scler. 2018;24(13):1776–8. https://doi.org/10.1177/1352458518771276.CrossRefPubMed

57.

Willis MD, Hope-Gill B, Flood-Page P, Joseph F, Needham E, Jones J, et al. Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Mult Scler. 2018;24(13):1779–82. https://doi.org/10.1177/1352458518790391.CrossRefPubMed

58.

Pfeuffer S. Sarcoidosis following alemtuzumab treatment: autoimmunity mediated by T cells and interferon-γ. Mult Scler. 2018;24(13):1783–4. https://doi.org/10.1177/1352458518804124.CrossRefPubMed

59.

Leussink VI, Reifenberger J, Hartung H-P. Case of alopecia universalis associated with alemtuzumab treatment in MS. Neurol Neuroimmunol Neuroinflamm. 2018;5:e454. https://doi.org/10.1212/NXI.0000000000000454.CrossRef

60.

Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, et al. Vitiligo after alemtuzumab treatment: secondary autoimmunity is not all about B cells. Neurology. 2018. https://doi.org/10.1212/WNL.0000000000006648.CrossRefPubMedPubMedCentral

61.

Rau D, Lang M, Harth A, Naumann M, Weber F, Tumani H, et al. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis—report of two cases. Int J Mol Sci. 2015;16:14669–76. https://doi.org/10.3390/ijms160714669.CrossRefPubMedPubMedCentral

62.

Canham LJW, Manara A, Fawcett J, Rolinski M, Mortimer A, Inglis KEA, et al. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2018;24:38–41. https://doi.org/10.1016/j.msard.2018.05.014.CrossRefPubMed

63.

Meunier B, Rico A, Seguier J, Boutiere C, Ebbo M, Harle JR, et al. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. Mult Scler. 2018;24:811–3. https://doi.org/10.1177/1352458517729766.CrossRefPubMed

64.

Saarela M, Senthil K, Jones J, Tienari PJ, Soilu-Hänninen M, Airas L, et al. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology. 2018;90:849–51. https://doi.org/10.1212/WNL.0000000000005420.CrossRefPubMed

65.

Brownlee WJ, Chataway J. Opportunistic infections after alemtuzumab: new cases of norcardial infection and cytomegalovirus syndrome. Mult Scler. 2017;23:876–7. https://doi.org/10.1177/1352458517693440.CrossRefPubMed

66.

Clerico M, de Mercanti S, Artusi CA, Durelli L, Naismith RT. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab. Mult Scler. 2017;23:874–6. https://doi.org/10.1177/1352458516688350.CrossRefPubMed

67.

Blasco MR, Ramos A, Malo CG, García-Merino A. Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis. J Neurol. 2017;264:168–9. https://doi.org/10.1007/s00415-016-8306-x.CrossRefPubMed

68.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, et al. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler. 2018. https://doi.org/10.1177/1352458518796675.CrossRefPubMed

69.

Pariani N, Willis M, Muller I, Healy S, Nasser T, McGowan A, et al. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. J Clin Endocrinol Metab. 2018;103:3010–8. https://doi.org/10.1210/jc.2018-00359.CrossRefPubMedPubMedCentral

70.

Steinman L. Induction of new autoimmune diseases after alemtuzumab therapy for multiple sclerosis: learning from adversity. JAMA Neurol. 2017;74:907–8. https://doi.org/10.1001/jamaneurol.2017.0325.CrossRefPubMed

71.

Graf J, Leussink VI, Dehmel T, Ringelstein M, Goebels N, Adams O, et al. Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. Ann Clin Transl Neurol. 2017;4:909–14. https://doi.org/10.1002/acn3.491.CrossRefPubMedPubMedCentral

72.

Guarnera C, Bramanti P, Mazzon E. Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2017;13:871–9. https://doi.org/10.2147/TCRM.S134398.CrossRefPubMedPubMedCentral

73.

Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics. 2013;10:55–67. https://doi.org/10.1007/s13311-012-0147-4.CrossRefPubMed

74.

Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373:1418–28. https://doi.org/10.1056/NEJMoa1501481.CrossRefPubMed

75.

Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue E-W, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167–75. https://doi.org/10.1016/S0140-6736(12)62190-4.CrossRefPubMed

76.

Kappos L, Havrdova E, Giovannoni G, Khatri BO, Gauthier SA, Greenberg SJ, et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler. 2017;23:1736–47. https://doi.org/10.1177/1352458516683266.CrossRefPubMed

77.

Benedict RH, Cohan S, Lynch SG, Riester K, Wang P, Castro-Borrero W, et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: results from the DECIDE study. Mult Scler. 2018;24:795–804. https://doi.org/10.1177/1352458517707345.CrossRefPubMed

78.

Lancet T. End of the road for daclizumab in multiple sclerosis. Lancet. 2018;391:1000. https://doi.org/10.1016/S0140-6736(18)30565-8.CrossRef

79.

Devlin M, Swayne A, Newman M, O’Gorman C, Brown H, Ong B, et al. A case of immune-mediated encephalitis related to daclizumab therapy. Mult Scler. 2018. https://doi.org/10.1177/1352458518792403.CrossRefPubMed

80.

Williams T, Chataway J. Immune-mediated encephalitis with daclizumab: the final nail. Mult Scler. 2018. https://doi.org/10.1177/1352458518791374.CrossRefPubMed

81.

European Medical Agency, Pharmacovigilance Risk Assessment Committee (PRAC). Assessment report on provisional measures, Procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data pharmacovigilance data Zinbryta, Procedure number: EMEA/H/A-20/1462/C/003862/0018; 2018. https://www.ema.europa.eu/documents/referral/zinbryta-article-20-referral-prac-assessment-report_en.pdf. Accessed 20 Aug 2018.

82.

Luessi F, Engel S, Spreer A, Bittner S, Zipp F. GFAPα IgG-associated encephalitis upon daclizumab treatment of MS. Neurol Neuroimmunol Neuroinflamm. 2018;5:e481. https://doi.org/10.1212/NXI.0000000000000481.CrossRefPubMedPubMedCentral

83.

Krueger JG, Kircik L, Hougeir F, Friedman A, You X, Lucas N, et al. Cutaneous adverse events in the randomized, double-blind, active-comparator DECIDE study of daclizumab high-yield process versus intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis. Adv Ther. 2016;33:1231–45. https://doi.org/10.1007/s12325-016-0353-2.CrossRefPubMedPubMedCentral

84.

Cortese I, Ohayon J, Fenton K, Lee C-C, Raffeld M, Cowen EW, et al. Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology. 2016;86:847–55. https://doi.org/10.1212/WNL.0000000000002417.CrossRefPubMedPubMedCentral

85.

Rauer S, Stork L, Urbach H, Stathi A, Marx A, Süß P, et al. Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy. Neurology. 2018;91:e359–63. https://doi.org/10.1212/WNL.0000000000005854.CrossRefPubMed

86.

Franks SE, Getahun A, Hogarth PM, Cambier JC. Targeting B cells in treatment of autoimmunity. Curr Opin Immunol. 2016;43:39–45. https://doi.org/10.1016/j.coi.2016.09.003.CrossRefPubMedPubMedCentral

87.

Schuh E, Berer K, Mulazzani M, Feil K, Meinl I, Lahm H, et al. Features of human CD3⁺CD20⁺ T cells. J Immunol. 2016;197:1111–7. https://doi.org/10.4049/jimmunol.1600089.CrossRefPubMed

88.

Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193:580–6. https://doi.org/10.4049/jimmunol.1400118.CrossRefPubMedPubMedCentral

89.

Wilk E, Witte T, Marquardt N, Horvath T, Kalippke K, Scholz K, et al. Depletion of functionally active CD20⁺ T cells by rituximab treatment. Arthritis Rheumatol. 2009;60:3563–71. https://doi.org/10.1002/art.24998.CrossRef

90.

Stüve O, Cepok S, Elias B, Saleh A, Hartung H-P, Hemmer B, Kieseier BC. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol. 2005;62:1620–3. https://doi.org/10.1001/archneur.62.10.1620.CrossRefPubMed

91.

Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons J-A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180:63–70. https://doi.org/10.1016/j.jneuroim.2006.06.029.CrossRefPubMedPubMedCentral

92.

Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88. https://doi.org/10.1056/NEJMoa0706383.CrossRefPubMed

93.

Alcalá C, Gascón F, Pérez-Miralles F, Gil-Perotín S, Navarré A, Boscá I, et al. Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study. J Neurol. 2018;265:1690–7. https://doi.org/10.1007/s00415-018-8899-3.CrossRefPubMed

94.

Scotti B, Disanto G, Sacco R, Guigli M, Zecca C, Gobbi C. Effectiveness and safety of rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLoS One. 2018;13:e0197415. https://doi.org/10.1371/journal.pone.0197415.CrossRefPubMedPubMedCentral

95.

Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, et al. Efficacy of rituximab in refractory RRMS. Mult Scler. 2018. https://doi.org/10.1177/1352458518772748.CrossRefPubMed

96.

Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, Piehl F. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 2018;75:320–7. https://doi.org/10.1001/jamaneurol.2017.4011.CrossRefPubMedPubMedCentral

97.

Spelman T, Frisell T, Piehl F, Hillert J. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Mult Scler. 2018;24:1087–95. https://doi.org/10.1177/1352458517713668.CrossRefPubMed

98.

Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, et al. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One. 2018;13:e0190425. https://doi.org/10.1371/journal.pone.0190425.CrossRefPubMedPubMedCentral

99.

Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 2016;87:2074–81. https://doi.org/10.1212/WNL.0000000000003331.CrossRefPubMedPubMedCentral

100.

Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460–71. https://doi.org/10.1002/ana.21867.CrossRefPubMed

101.

Hartung H-P, Aktas O. Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope. Ann Neurol. 2009;66:429–32. https://doi.org/10.1002/ana.21880.CrossRefPubMed

102.

Mitka M. FDA: increased HBV reactivation risk with ofatumumab or rituximab. JAMA. 2013;310:1664. https://doi.org/10.1001/jama.2013.281115.CrossRefPubMed

103.

Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, et al. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: the Preblin study. PLoS One. 2017;12:e0184550. https://doi.org/10.1371/journal.pone.0184550.CrossRefPubMedPubMedCentral

104.

Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, et al. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler. 2018;24(9):1224–33. https://doi.org/10.1177/1352458517720044.CrossRefPubMed

105.

Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834–40. https://doi.org/10.1182/blood-2008-10-186999.CrossRefPubMedPubMedCentral

106.

Tallantyre EC, Whittam DH, Jolles S, Paling D, Constantinesecu C, Robertson NP, et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018;265:1115–22. https://doi.org/10.1007/s00415-018-8812-0.CrossRefPubMedPubMedCentral

107.

Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy—rare but there! Leuk Lymphoma. 2009;50:1083–95. https://doi.org/10.1080/10428190902934944.CrossRefPubMed

108.

Rissanen E, Remes K, Airas L. Severe neutropenia after rituximab-treatment of multiple sclerosis. Mult Scler Relat Disord. 2018;20:3–5. https://doi.org/10.1016/j.msard.2017.12.005.CrossRefPubMed

109.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–34. https://doi.org/10.1056/NEJMoa1601277.CrossRefPubMed

110.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209–20. https://doi.org/10.1056/NEJMoa1606468.CrossRefPubMed

111.

Kappos L, Li D, Calabresi PA, O’Connor P, Bar-Or A, Barkhof F, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378:1779–87. https://doi.org/10.1016/S0140-6736(11)61649-8.CrossRefPubMed

112.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung H-P, Kappos L, et al. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Mult Scler J Exp Transl Clin. 2018;4:2055217318760642. https://doi.org/10.1177/2055217318760642.CrossRefPubMedPubMedCentral

113.

Hauser S. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Platform presentation number S36.001. AAN Annual Meeting; 2018. http://n.neurology.org/content/90/15_Supplement/S36.001. Accessed 20 Aug 2018.

114.

Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014;82:573–81. https://doi.org/10.1212/WNL.0000000000000125.CrossRefPubMed

115.

Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology. 2018;90:e1805–14. https://doi.org/10.1212/WNL.0000000000005516.CrossRefPubMedPubMedCentral

116.

Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci. 2005;8:745–51. https://doi.org/10.1038/nn1460.CrossRefPubMed

117.

Mi S, Miller RH, Tang W, Lee X, Hu B, Wu W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol. 2009;65:304–15. https://doi.org/10.1002/ana.21581.CrossRefPubMed

118.

Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, Yuan Q, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med. 2007;13:1228–33. https://doi.org/10.1038/nm1664.CrossRefPubMed

119.

Aktas O, Albrecht P, Hartung H-P. Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives. Curr Opin Neurol. 2016;29:199–204. https://doi.org/10.1097/WCO.0000000000000327.CrossRefPubMed

120.

Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:189–99. https://doi.org/10.1016/S1474-4422(16)30377-5.CrossRefPubMed

121.

Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch LJ, et al. Predictors of response to opicinumab in acute optic neuritis. Ann Clin Transl Neurol. 2018;41:1017. https://doi.org/10.1002/acn3.620.CrossRef

122.

Ranger A, Ray S, Szak S, Dearth A, Allaire N, Murray R, et al. Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies. Neurol Neuroimmunol Neuroinflamm. 2018;5:e417. https://doi.org/10.1212/NXI.0000000000000417.CrossRefPubMed

123.

Kremer D, Göttle P, Hartung H-P, Küry P. Pushing forward: remyelination as the new frontier in CNS diseases. Trends Neurosci. 2016;39:246–63. https://doi.org/10.1016/j.tins.2016.02.004.CrossRefPubMed

124.

Moccia M, de Stefano N, Barkhof F. Imaging outcome measures for progressive multiple sclerosis trials. Mult Scler. 2017;23:1614–26. https://doi.org/10.1177/1352458517729456.CrossRefPubMedPubMedCentral

125.

Šega-Jazbec S, Barun B, Horvat Ledinek A, Fabekovac V, Krbot Skorić M, Habek M. Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis. Mult Scler Relat Disord. 2017;17:151–3. https://doi.org/10.1016/j.msard.2017.07.019.CrossRefPubMed

126.

Fabian M. Pregnancy in the setting of multiple sclerosis. Continuum (Minneap Minn). 2016;22:837–50. https://doi.org/10.1212/CON.0000000000000328.CrossRef

127.

Voskuhl R, Momtazee C. Pregnancy: effect on multiple sclerosis, treatment considerations, and breastfeeding. Neurotherapeutics. 2017;14:974–84. https://doi.org/10.1007/s13311-017-0562-7.CrossRefPubMedPubMedCentral

128.

Houtchens MK, Edwards NC, Phillips AL. Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. Neurology. 2018;91:e1570–8. https://doi.org/10.1212/WNL.0000000000006382.CrossRefPubMedPubMedCentral

129.

European Medical Agency. Tysabri summary of product characteristics; 2018. https://ec.europa.eu/health/documents/community-register/2018/20180802142037/anx_142037_en.pdf. Accessed 20 Nov 2018.

130.

European Medical Agency. Lemtrada summary of product characteristics; 2018. https://www.ema.europa.eu/documents/product-information/lemtrada-epar-product-information_en.pdf. Accessed 20 Nov 2018.

131.

European Medical Agency. Ocrevus summary of product characteristics; 2018. https://www.ema.europa.eu/documents/product-information/ocrevus-epar-product-information_en.pdf. Accessed 20 Nov 2018.

132.

Trojano M, Tintore M, Montalban X, Hillert J, Kalincik T, Iaffaldano P, et al. Treatment decisions in multiple sclerosis - insights from real-world observational studies. Nat Rev Neurol. 2017;13:105–18. https://doi.org/10.1038/nrneurol.2016.188.CrossRefPubMed

Springer Medizin

Monoclonal Antibodies for Multiple Sclerosis: An Update

Abstract

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar

Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial

FKB327: An Adalimumab Biosimilar

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies

A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects

Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities